Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine Among Virologically Suppressed Children, 6 to Less Than 12 Years of Age, Living With HIV-1

NCT05674656 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT05674656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05674656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine Among Virologically Suppressed Children, 6 to Less Than 12 Years of Age, Living With HIV-1
Lead sponsor
ViiV Healthcare
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 6, 2023
Completion date
May 3, 2028
Enrollment
20 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections